LUMIBIRD: BANKS NEW CONFIDENCE IN THE GROUP’S STRATEGY WITH FINANCING OF MORE THAN €100 M | 15.10.24

Lannion, October 15, 2024 – 5:45 pm

LUMIBIRD: BANKS RENEW CONFIDENCE IN THE GROUP’S STRATEGY WITH FINANCING OF MORE THAN €100 M

• 55.2 million repayable over 7 years, to reschedule existing loans
• 50 million will be withdrawn in 3 years to finance acquisitions

The LUMIBIRD Group (FR0000038242 – LBIRD), European leader in laser technologies, announces that it has finalized bank financing of more than 100 million euros to reschedule its current loans, especially taking into account the maturity of its bond debt, and to finance potential acquisition opportunities.

The financing round includes Crédit Agricole Côte d’Armor (main bank), Arkéa Banque Entreprises et Institutionnels, Banque Populaire Grand Ouest, Caisse d’Epargne Bretagne Pays de Loire and LCL. All of these banks are part of Lumibird’s historic banking pool: through this financing, they renew their confidence in the Group’s strategy.

This financing consists of two lines:

• 55.2 million euros repayable over 7 years, to reschedule existing loans, especially taking into account the maturity of its bond debt;
• 50 million euros* that can be used over 3 years, with 40% repayable upon maturity and the remainder amortizable over a total period of 7 years.

The tariff spread applied remains the same as the previous round, in December 2020.

Marc Le Flohic, president and CEO of Lumibird, said: “The renewed confidence shown by our banking partners is a strong signal at a time when Lumibird needs to demonstrate its ability to increase profitability.”

*Line not confirmed

Next date: Q3 2024 revenues, 10/21/2024 after close of trading

LUMIBIRD is one of the world’s leading laser experts. With 50 years of experience and knowledge in solid-state, diode and fiber laser technologies, the Group designs, manufactures and distributes high-performance laser solutions through two divisions: Photonics and Medical. The Photonics Division designs and produces components, lasers and systems for the defense and space, environmental, surveying and security, industrial and scientific and medical technology markets. The Medical branch designs and produces medical diagnostic and treatment systems for ophthalmology.
As a result of the merger in October 2017 between the Keopsys and Quantel groups, LUMIBIRD, with more than 1,000 employees and more than 203.6 million euros in sales in 2023, is present in Europe, America and Asia.
LUMIBIRD shares are listed in compartment B of Euronext Paris. FR0000038242 – LBIRD www.lumibird.com
LUMIBIRD is a member of Euronext Technology leaders since 2022.

Contacts

• 241015_ LUMIBIRD_Financement_bancaire_EN